[Federal Register Volume 65, Number 216 (Tuesday, November 7, 2000)]
[Rules and Regulations]
[Pages 66619-66620]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-28520]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 524


Ophthalmic and Topical Dosage Form New Animal Drugs; 
Enrofloxacin, Silver Sulfadiazine Emulsion

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
drug regulations to reflect approval of a new animal drug application 
(NADA) filed by Bayer Corp., Agriculture Division, Animal Health. The 
NADA provides for veterinary prescription use of an enrofloxacin/silver 
sulfadiazine otic emulsion to treat otitis externa in dogs.

DATES: This rule is effective November 7, 2000.

FOR FURTHER INFORMATION CONTACT: Melanie R. Berson, Center for 
Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 
Standish Pl., Rockville, MD 20855, 301-827-7540.

SUPPLEMENTARY INFORMATION: Bayer Corp., Agriculture Division, Animal 
Health, P.O. Box 390, Shawnee Mission, KS 66201, filed NADA 141-176 
that provides for veterinary prescription use of BAYTRIL (0.5 
% enrofloxacin/1.0% silver sulfadiazine) Otic Emulsion for the 
treatment of otitis externa in dogs. The NADA is approved as of 
September 29, 2000, and the regulations are amended in 21 CFR part 524 
by adding new section 524.802 to reflect the approval. The basis of 
approval is discussed in the freedom of information summary.
    In accordance with the freedom of information provisions of 21 CFR 
part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
data and information submitted to support approval of this application 
may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 
between 9 a.m. and 4 p.m., Monday through Friday.
    Under section 512(c)(2)(F)(ii) of the Federal Food, Drug, and 
Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(ii)), this approval qualifies for 
3 years of marketing exclusivity beginning September 29, 2000, because 
the application contains substantial evidence of effectiveness of the 
drug involved, or any studies of animal safety, required for approval 
of the application and conducted or sponsored by the applicant.
    The agency has determined under 21 CFR 25.33(d)(1) that this action 
is of a type that does not individually or cumulatively have a 
significant effect on the human environment. Therefore, neither an 
environmental assessment nor an environmental impact statement is 
required.
    This rule does not meet the definition of ``rule'' in 5 U.S.C. 
804(3)(A) because it is a rule of ``particular applicability.'' 
Therefore, it is not subject to the congressional review requirements 
in 5 U.S.C. 801-808.

List of Subjects in 21 CFR Part 524

    Animal drugs.


[[Page 66620]]


    Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
authority delegated to the Commissioner of Food and Drugs and 
redelegated to the Center for Veterinary Medicine, 21 CFR part 524 is 
amended as follows:

PART 524--OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

    1. The authority citation for 21 CFR part 524 continues to read as 
follows:

    Authority: 21 U.S.C. 360b.

    2. Section 524.802 is added to read as follows:


Sec. 524.802  Enrofloxacin, silver sulfadiazine emulsion.

    (a) Specifications. Each milliliter contains 5 milligrams (mg) 
enrofloxacin and 10 mg silver sulfadiazine.
    (b) Sponsor. See No. 000859 in Sec. 510.600(c) of this chapter.
    (c) Conditions of use--Dogs--(1) Amount. 5 to 10 drops for dogs 
weighing 35 pounds (lb) or less and 10 to 15 drops for dogs weighing 
more than 35 lb; applied twice daily for up to 14 days.
    (2) Indications for use. For the treatment of otitis externa in 
dogs.
    (3) Limitations. Federal law restricts this drug to use by or on 
the order of a licensed veterinarian. Federal law prohibits the extra-
label use of this drug in food-producing animals.

    Dated: October 26, 2000.
Stephen F. Sundlof,
Director, Center for Veterinary Medicine.
[FR Doc. 00-28520 Filed 11-6-00; 8:45 am]
BILLING CODE 4160-01-F